Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference


Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 2:40 p.m. GMT (9:40 a.m. ET) in London, England.

A live webcast of the presentation can be accessed in the Investors & Media section of Bicycle's website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the presentation date.

About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle's lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.


These press releases may also interest you

at 16:54
Dell Technologies Inc. (the "Company" or "Dell Technologies") announced today the pricing of the previously announced private offering by two of its wholly-owned subsidiaries, Dell International L.L.C. and EMC Corporation, as co-issuers (the...

at 16:48
As businesses across the world are confronted with the impacts of the coronavirus, Zurich Insurance has launched a new podcast series, Risk Insights: Coronavirus. The series brings together key risk management leaders sharing their knowledge to help...

at 16:45
NI today announced that $2.5 million will be immediately deployed from the National Instruments Fund, a donor advised fund established by NI in 2019 with the Austin Community Foundation, to support global and local COVID-19 relief efforts. The...

at 16:45
Danaher Corporation ("Danaher") announced today that it has priced a reopening of: ?150,000,000 principal amount of additional 1.700% senior notes due 2024 at an offering price of 100.298% of the principal amount, plus accrued interest from and...

at 16:35
Sage Therapeutics, Inc. , a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on April 1, 2020, the Compensation...

at 16:35
SmileDirectClub, the industry pioneer and first direct-to-consumer medtech platform for teeth straightening, today announced the company will extend its SmileShop closures until at least May 3, 2020. The extended closure of SmileShops in all markets...



News published on 14 november 2019 at 07:05 and distributed by: